Mankind Pharma Announces 35th AGM on August 4, 2026, via Video Conferencing
Mankind Pharma Limited will hold its 35th Annual General Meeting on August 4, 2026, via Video Conferencing. Remote e-voting will be available from August 1 to August 30, 2026. The Annual Report for FY 2025-26 has been distributed. Members are also reminded to claim any unclaimed interim dividends for FY 2025-26.
This is a standard procedural announcement for an AGM and does not involve any new business, financial results, or strategic decisions that would significantly impact the company's operations or stock.
The announcement is a routine corporate communication regarding the Annual General Meeting and dividend claims, with no significant positive or negative financial or strategic developments.
Mankind Pharma Limited has announced its Thirty-Fifth Annual General Meeting (35th AGM), which will be held on Tuesday, August 4, 2026. The meeting will be conducted through Video Conferencing (VC) and Other Audio-Visual Means (OAVM) in compliance with applicable provisions of the Companies Act, 2013, and relevant circulars. The company has also provided information regarding e-voting for its shareholders. The Annual Report for the financial year 2025-26 has been dispatched to members via email and post, and is also available on the company's website and stock exchange platforms. Shareholders who have not registered their email addresses are advised to do so. The notice details the process for remote e-voting, which will commence on August 1, 2026, and end on August 30, 2026. Shareholders who have registered their email addresses and opted for remote e-voting will not be able to vote again during the AGM. The company has appointed a scrutinizer to ensure the fair and transparent conduct of the e-voting process. Voting results will be declared within two working days of the AGM's conclusion. Additionally, the announcement mentions that members who have not yet claimed or encashed their interim dividend for the financial year 2025-26 are requested to submit their claims without undue delay.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.